VTVT vTv Therapeutics Inc.

1.5
-0.04  -3%
Previous Close 1.54
Open 1.56
Price To Book -2
Market Cap 93,964,320
Shares 62,642,880
Volume 71,155
Short Ratio
Av. Daily Volume 179,612
Stock charts supplied by TradingView

NewsSee all news

  1. vTv Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

    HIGH POINT, N.C., Dec. 02, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and

  2. vTv Therapeutics Announces 2019 Third Quarter Financial Results and Update

    SimpliciT-1 Study of TTP399 in patients with type 1 diabetes fully-enrolled Elevage Study of azeliragon in patients with mild Alzheimer's disease with type 2 diabetes actively enrolling HIGH POINT, N.C., Oct. 30, 2019

  3. vTv to Host Key Opinion Leader Event to Discuss the Type 1 Diabetes Treatment Landscape and Emerging Therapies as Adjuncts to Insulin

    HIGH POINT, N.C., Oct. 03, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), today announced that the Company will host a key opinion leader (KOL) presentation and webcast discussing the type 1 diabetes

  4. vTv Therapeutics Presents Additional Positive Data from the Phase 2 Simplici-T1 Study in Patients with Type 1 Diabetes at 55th Annual Meeting of the European Association for the Study of Diabetes

    HIGH POINT, N.C., Sept. 18, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), today presented additional positive data from its phase 2 Simplici-T1 study in patients with type 1 diabetes (T1D) at the 55th

  5. vTv Therapeutics to Present Posters at Two Scientific Conferences in September

     Presenting New Clinical Data from Phase 2 Study in Type 1 Diabetes with Liver Selective GKA Program Pre-Clinical Data in NASH with the NRF2/Bach1 Program  HIGH POINT, N.C., Sept. 11, 2019 (GLOBE NEWSWIRE) -- vTv

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 Part 2 data due late-1Q 2020.
TTP399
Type 1 Diabetes
Phase 2 data released August 2016. Primary endpoint met.
TTP399 - AGATA
Type 2 Diabetes
Phase 2 primary endpoint met - December 14, 2016.
TTP273 - LOGRA
Type 2 Diabetes
Phase 3 data both Part A (April 9, 2018) and Part B (June 12, 2018) did not meet endpoints.
Azeliragon - STEADFAST
Mild Alzheimer’s disease
Phase 2/3 top-line data due late 2020 or early 2021.
Azeliragon
Mild Alzheimer’s disease with type 2 diabetes

Latest News

  1. vTv Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

    HIGH POINT, N.C., Dec. 02, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and

  2. vTv Therapeutics Announces 2019 Third Quarter Financial Results and Update

    SimpliciT-1 Study of TTP399 in patients with type 1 diabetes fully-enrolled Elevage Study of azeliragon in patients with mild Alzheimer's disease with type 2 diabetes actively enrolling HIGH POINT, N.C., Oct. 30, 2019

  3. vTv to Host Key Opinion Leader Event to Discuss the Type 1 Diabetes Treatment Landscape and Emerging Therapies as Adjuncts to Insulin

    HIGH POINT, N.C., Oct. 03, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), today announced that the Company will host a key opinion leader (KOL) presentation and webcast discussing the type 1 diabetes

  4. vTv Therapeutics Presents Additional Positive Data from the Phase 2 Simplici-T1 Study in Patients with Type 1 Diabetes at 55th Annual Meeting of the European Association for the Study of Diabetes

    HIGH POINT, N.C., Sept. 18, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), today presented additional positive data from its phase 2 Simplici-T1 study in patients with type 1 diabetes (T1D) at the 55th

  5. vTv Therapeutics to Present Posters at Two Scientific Conferences in September

     Presenting New Clinical Data from Phase 2 Study in Type 1 Diabetes with Liver Selective GKA Program Pre-Clinical Data in NASH with the NRF2/Bach1 Program  HIGH POINT, N.C., Sept. 11, 2019 (GLOBE NEWSWIRE) -- vTv

  6. vTv Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    HIGH POINT, N.C., Sept. 04, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for diabetes and